Aflibercept Off-Target Effects in Diabetic Macular Edema: An In Silico Modeling Approach

Area of Science:

• Ophthalmology
• Pharmacology
• Computational Biology

Background:

• Diabetic macular edema (DME) is a leading cause of vision loss in diabetic patients.
• Intravitreal aflibercept injection (IAI) is a standard treatment for DME, but its precise mechanism of action (MoA) requires further elucidation.
• Understanding IAI's multi-target MoA is crucial for optimizing DME treatment strategies.

Purpose of the Study:

• To explore the detailed MoA of IAI in diabetic macular edema (DME) pathophysiology.
• To investigate the multi-target nature of IAI using an in silico disease model.
• To evaluate the specific role of VEGFR1 pathway inhibition in DME treatment.

Main Methods:

• Utilized the Therapeutic Performance Mapping System to create mathematical models of DME pathophysiology.
• Simulated the effects of IAI on vascular endothelial growth factor receptors (VEGFRs) and DME-related processes.
• Performed enrichment analysis and visualized predicted protein activity to understand IAI's impact.

Main Results:

• The in silico model simulated DME pathophysiology and IAI's MoA via VEGFR1 and VEGFR2 inhibition.
• IAI significantly modulated key DME processes, including angiogenesis, blood-retinal barrier integrity, and inflammation.
• VEGFR1 pathway inhibition was identified as critical for modulating inflammatory effectors.

Conclusions:

• IAI's MoA involves simultaneous inhibition of VEGFR1 and VEGFR2 signaling pathways.
• IAI demonstrates therapeutic advantages in DME by targeting angiogenesis, barrier function, and inflammation.
• Sustained VEGFR1 pathway inhibition by IAI may offer significant benefits for DME patients.